Trials / Completed
CompletedNCT02634853
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye
A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 429 (actual)
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 1% Tavilermide Ophthalmic Solution | 1% Tavilermide BID Dosing |
| DRUG | Placebo Ophthalmic Solution | Vehicle Ophthalmic Solution |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2017-02-01
- Completion
- 2017-03-01
- First posted
- 2015-12-18
- Last updated
- 2019-08-16
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02634853. Inclusion in this directory is not an endorsement.